BioCentury | Aug 8, 2020
Product Development

First oral SMA therapy will be delivered to patients’ homes, well placed for virtual launch

FDA’s early approval on Friday of the first oral spinal muscular atrophy treatment, Evrysdi risdiplam, leaves Genentech and PTC well positioned for a virtual launch amidst COVID-19. The Roche (SIX:ROG; OTCQX:RHHBY) unit will begin to...
BioCentury | Aug 7, 2020
Management Tracks

Greene, an architect of Alnylam, looks to the next chapter

Barry Greene, who has worked with CEO John Maraganore to build Alnylam for the past 17 years, will depart the RNAi company as president at the end of the quarter. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said...
BioCentury | Aug 6, 2020
Deals

Data Bytes: 2020’s top 10 gene and cell therapy deals to date

The cell and gene therapy field continues to be a driver of high-value deals frequently breaking the billion dollar mark. Eight of the 10 largest cell and gene therapy deals so far this year have...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

COO Franz-Werner Haas will become CureVac AG ’s permanent CEO, the mRNA vaccines company’s third this year. He has filled the role on an interim basis since mid-March. CEO Ingmar Hoerr took a leave of...
BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

Six months after the last round of price cuts for generics and off-patent originator drugs in China’s centralized procurement program, the Chinese government has outlined plans to nearly double the number of included drug formulations....
BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Promoting degradation of the MDM2 oncogene for liposarcoma

DISEASE CATEGORY: Cancer INDICATION: Sarcoma A pyrido-indole-based tool compound that triggers degradation of MDM2, an enzyme that suppresses p53 expression, could treat liposarcoma. In 10 human liposarcoma cell lines, the compound inhibited growth with IC...
BioCentury | Jul 25, 2020
Regulation

FDA makes Gilead’s Tecartus, for mantle cell lymphoma, third U.S.-approved CAR T

Kite’s Tecartus has become the third CAR T cell therapy, after Kymriah and Yescarta, to earn FDA approval. On Friday, FDA granted accelerated approval to Tecartus brexucabtagene autoleucel from the Gilead Sciences Inc. (NASDAQ:GILD) unit...
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

New base editors widen template-free editing options  A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM) co-founder Keith Joung, and a Chinese Academy of Sciences team have separately developed a new class of...
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

Among the 11 new medicines recommended for approval by EMA’s CHMP is the first antibody-drug conjugate, and most advanced BCMA-targeted agent, for multiple myeloma patients: GSK’s Blenrep belantamab mafodotin. FDA’s Oncologic Drugs Advisory Committee unanimously...
Items per page:
1 - 10 of 10433
BioCentury | Aug 8, 2020
Product Development

First oral SMA therapy will be delivered to patients’ homes, well placed for virtual launch

FDA’s early approval on Friday of the first oral spinal muscular atrophy treatment, Evrysdi risdiplam, leaves Genentech and PTC well positioned for a virtual launch amidst COVID-19. The Roche (SIX:ROG; OTCQX:RHHBY) unit will begin to...
BioCentury | Aug 7, 2020
Management Tracks

Greene, an architect of Alnylam, looks to the next chapter

Barry Greene, who has worked with CEO John Maraganore to build Alnylam for the past 17 years, will depart the RNAi company as president at the end of the quarter. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said...
BioCentury | Aug 6, 2020
Deals

Data Bytes: 2020’s top 10 gene and cell therapy deals to date

The cell and gene therapy field continues to be a driver of high-value deals frequently breaking the billion dollar mark. Eight of the 10 largest cell and gene therapy deals so far this year have...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

COO Franz-Werner Haas will become CureVac AG ’s permanent CEO, the mRNA vaccines company’s third this year. He has filled the role on an interim basis since mid-March. CEO Ingmar Hoerr took a leave of...
BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

Six months after the last round of price cuts for generics and off-patent originator drugs in China’s centralized procurement program, the Chinese government has outlined plans to nearly double the number of included drug formulations....
BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Promoting degradation of the MDM2 oncogene for liposarcoma

DISEASE CATEGORY: Cancer INDICATION: Sarcoma A pyrido-indole-based tool compound that triggers degradation of MDM2, an enzyme that suppresses p53 expression, could treat liposarcoma. In 10 human liposarcoma cell lines, the compound inhibited growth with IC...
BioCentury | Jul 25, 2020
Regulation

FDA makes Gilead’s Tecartus, for mantle cell lymphoma, third U.S.-approved CAR T

Kite’s Tecartus has become the third CAR T cell therapy, after Kymriah and Yescarta, to earn FDA approval. On Friday, FDA granted accelerated approval to Tecartus brexucabtagene autoleucel from the Gilead Sciences Inc. (NASDAQ:GILD) unit...
BioCentury | Jul 25, 2020
Translation in Brief

New class of cytosine base editors; plus new U.K. vaccine manufacturing facilities, scalable surrogate assay for COVID-19; combating antibiotic resistance and

New base editors widen template-free editing options  A Massachusetts General Hospital team co-led by Beam Therapeutics Inc. (NASDAQ:BEAM) co-founder Keith Joung, and a Chinese Academy of Sciences team have separately developed a new class of...
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

Among the 11 new medicines recommended for approval by EMA’s CHMP is the first antibody-drug conjugate, and most advanced BCMA-targeted agent, for multiple myeloma patients: GSK’s Blenrep belantamab mafodotin. FDA’s Oncologic Drugs Advisory Committee unanimously...
Items per page:
1 - 10 of 10433